论文部分内容阅读
作者以前的研究和临床试验表明,使用低剂量重组乙型肝炎疫苗也能获得良好的抗-HBs阳转率.作者在新西兰儿童中对两种低剂量酵母重组疫苗的免疫原性进行了比较.将201名1～12岁的儿童随机分为两组:一组(99人)接种3剂Merck药厂(MSD)生产的重组疫苗,每剂2μg;另一组(102人)接种3剂Smith Kline药厂(SKF)生产的重组疫苗,剂量同上,均为三角肌接种,免疫程序为0、1、2月.于接种第3针后4～6周采血.在接种了3剂2μg MSD血源性
The authors previous studies and clinical trials have shown that good anti-HBs positive rates are also achieved with low-dose recombinant hepatitis B. The immunogenicity of two low-dose recombinant yeast vaccines was compared in New Zealand children. 201 children aged 1 to 12 years were randomly assigned to two groups: one group (99) received 3 doses of recombinant vaccine produced by Merck Pharmaceuticals (MSD) at 2 μg per dose; the other group (102) received 3 doses of Smith The recombinant vaccine produced by Kline Pharmaceutical Factory (SKF) was dose-administered as above, with deltoid inoculations administered for 0, 1, and 2 months. Blood was taken 4 to 6 weeks after the third needle inoculation. Source